ATS Corporation account plan
Global manufacturing automation solutions
At a glance
ATS Corporation is a Canadian builder of automated manufacturing and assembly systems, with $2,972.9M of fiscal 2026 revenues and over 7,000 people.
ATS Corporation, founded in 1978 and listed on the TSX and NYSE, plans, designs, builds, commissions and services automated manufacturing and assembly systems, automation products and test solutions, favouring regulated industries such as life sciences and nuclear. It employs over 7,000 people at more than 65 manufacturing facilities and over 85 offices in North America, Europe, Asia and Oceania. In fiscal 2026 (year ended March 31, 2026) revenues were $2,972.9M (+17.4%), adjusted EBITDA $413.0M and net income $71.7M. Order Bookings were $2,952M and backlog $1,958M at year-end.
Business units
Life Sciences
$1,522.0M of fiscal 2026 adjusted revenue (about 51%, computed)Automation for medical devices, auto-injectors, pharmaceuticals, radiopharmaceuticals, pharmacy and laboratory operations, with brands including Comecer, Heidolph, BioDot, Avidity and Scientific Products. Q2 fiscal 2027 revenue fell 5.0% on normalised GLP-1 activity, but backlog reached $1,238M, a record for the market, on radiopharmaceutical and medical device orders.
Industrial & Consumer
Formed in fiscal 2027 from Consumer Products ($553.0M of fiscal 2026 adjusted revenue) and repositioned former transportation businesses. It covers personal care and household goods automation, warehouse packaging automation and specialised industrial applications; Q2 fiscal 2027 revenue fell 23.5% as packaging orders were delayed by U.S. tariffs.
Food & Beverage
$498.8M of fiscal 2026 adjusted revenue (about 17%, computed)Food processing and packaging, beverage filling, optical sorting and inspection under brands such as NCC, MARCO, CFT and Paxiom, with strong recognition in tomato processing. Revenue rose 19.6% in fiscal 2026 but fell 20.2% in Q2 fiscal 2027 on lower tomato processing orders.
Energy
$226.6M of fiscal 2026 adjusted revenue (about 8%, computed)Automation for nuclear refurbishment (CANDU), small modular reactors, fuel fabrication and waste handling, plus other energy applications. Revenue rose 82.7% in fiscal 2026 and 45.1% in Q2 fiscal 2027 on nuclear project execution.
Strategic priorities
- 15% margin target
- ATS aims to expand its adjusted earnings from operations margin to 15% over time from about 10%, and CEO Doug Wright believes it can operate above that target.
- Fixed Cost Transformation Program
- A multi-phase program designed to deliver $65M-$75M of annualised savings, about 250 basis points of margin, cutting about 10% of square footage and 300 to 400 workers including subcontractors.
- Radiopharma and nuclear growth
- ATS is adding capacity in radiopharma, including the Bologna facility expansion and service centers in the central United States and Melbourne, and expects to expand U.S. facilities for nuclear.
- Reoccurring revenue and aftermarket
- Reoccurring revenues are expected at 25%-35% of revenues, with services embedded into operating units and digital and data-driven services developed.
- Disciplined acquisitions
- Growth through acquisition remains part of the Build, Grow and Expand strategy, under a cash return on investment framework that sets return thresholds.
Latest results
In Q2 fiscal 2027 (quarter ended September 27, 2026) revenues fell 8.6% to $665.8M from $728.5M, mainly on normalised GLP-1-related activity, and adjusted earnings from operations fell to $57.4M (8.6% margin) from $79.1M (10.9%). ATS posted a net loss of $5.0M. Order Bookings rose 12.7% to $827M, led by Life Sciences, and backlog stood at $2,009M. Because packaging orders were delayed by U.S. Section 338 tariffs, management no longer expects modest revenue growth and margin expansion in fiscal 2027; Q3 revenue is guided at $640M-$680M.
Investments and deals
- Acquisitions
- Heidolph and Paxiom contributed $43.2M of revenue in fiscal 2026; the acquisition pipeline is described as healthy across several end markets.
- Capital expenditure
- Fiscal 2027 capex is now expected at $60M-$80M.
- Facility sales
- After Q2 fiscal 2027, two U.S. facilities were sold for $71.2M, one leased back to support the U.S. nuclear business, helping fund restructuring.
- Share buybacks
- 2,244,461 shares were repurchased under the NCIB for $61.3M in fiscal 2027 to date.
Challenges and risks
- U.S. tariffs
- Section 338 tariffs hit packaging equipment made in Canada and sold into the U.S.; sales from Canadian and European operations into the U.S. are just over 20% of adjusted revenues.
- GLP-1 normalisation
- Lower GLP-1-related activity drove a $66.1M organic revenue decline in Q2 fiscal 2027.
- Leverage
- Net debt to pro forma adjusted EBITDA was 3.1 times, expected to remain moderately above the 2.0-3.0 times range for the rest of fiscal 2027.
- Internal controls
- Disclosure controls are not effective because of a material weakness in one international division linked to ERP transition delays.
- Underused capacity
- The CEO's review found portions of the business with excess capacity and infrastructure not generating required returns, notably in Europe.
What leadership says
“Growth through acquisition will remain a key component of our strategy”
“I have even more conviction today than I did in coming to ATS”
“These are whole factories that are being implemented by these customers in radiopharma and med device”
“we do not expect to achieve our previous goals for modest revenue growth and for margin expansion in the year”
Where a supplier can help
- Footprint consolidation services
- Tied to the Fixed Cost Transformation Program: facility closures, equipment relocation and real estate advisory as square footage falls by about 10%.
- Components for radiopharma and nuclear builds
- Tied to the radiopharma and nuclear growth priority: containment, shielding, precision components and U.S. manufacturing capacity for whole-factory projects.
- ERP and controls remediation
- Tied to the internal controls challenge: ERP implementation and audit partners for the international division's transition.
- Aftermarket and digital service tools
- Tied to the reoccurring revenue priority: field service software, connected-equipment analytics and spare parts logistics.
- Trade and supply chain advisory
- Tied to the U.S. tariffs challenge: customs, sourcing and production-shifting support for Canadian-made equipment sold into the U.S.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like ATS Corporation?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- ATS Corporation 2026 Annual Report (fiscal year ended March 31, 2026)
- ATS Corporation (TSX/NYSE: ATS, Cambridge, Ontario) plans, designs, builds, commissions and services automated manufacturing and assembly systems, automation products and test solutions; founded in 1978, over 7,000 people, more than 65 manufacturing facilities and over 85 offices. Orise (process automation and digital solutions) is one of its subsidiary brands.
- Fiscal 2026 (year to March 31, 2026): revenues $2,972.9M (+17.4%); adjusted revenues $2,970.1M (+10.8%); adjusted earnings from operations $314.4M (10.6% margin); adjusted EBITDA $413.0M (13.9%); net income $71.7M; adjusted basic EPS $1.69 (all CAD).
- Adjusted revenue by market: Life Sciences $1,522.0M, Consumer Products $553.0M, Food and Beverage $498.8M, Energy $226.6M, Transportation $169.7M; by region North America $1,558.6M, Europe $1,020.5M, Asia/Other $391.0M.
- Order Bookings fell 10.7% to $2,952M (organic -14.4%) and backlog to $1,958M (-8.5%) after large life sciences enterprise orders the year before; trailing book-to-bill 0.99:1.
- Strategy is Build, Grow and Expand on the ATS Business Model (ABM); goal of a 15% adjusted earnings from operations margin over time, growth of products, after-sales services and digital, and disciplined M&A. Reoccurring revenues expected at 25%-35% of revenue.
- Transportation (mainly EV) is being wound down: $28.3M of reorganization costs in Q4, three U.S. facilities to close, buildings in the U.S. and Germany held for sale, about $50M of dilutive revenue to be removed in fiscal 2027; transportation will stop being reported as a separate market.
- Fiscal 2027 outlook at publication: modest revenue growth, margin up about 50-75 bps, capex $70M-$90M, leverage within 2.0-3.0x (2.8x at year-end); free cash flow $371.7M in fiscal 2026.
- Governance: CEO Doug Wright in his first six months, Interim CFO Anne Cybulski, Michael Martino (Mason Capital) chair of the board; internal control over financial reporting not effective at March 31, 2026 (ERP transition delays in one international division).
- ATS Corporation MD&A for the quarter ended September 27, 2026 (Q2 fiscal 2027)
- Q2 fiscal 2027 (quarter to September 27, 2026): revenues $665.8M (-8.6%; organic -9.1%), net loss $5.0M, adjusted earnings from operations $57.4M (8.6% margin vs 10.9%), adjusted EBITDA $80.7M (12.1%), adjusted basic EPS $0.27 (CAD).
- Order Bookings $827M (+12.7%), including the highest life sciences quarter since Q2 fiscal 2025; trailing book-to-bill about 1.05:1; backlog $2,009M (-2.9%).
- Markets are now Life Sciences, Industrial & Consumer, Food & Beverage and Energy (transportation folded in). Q2 revenue: Life Sciences $355.8M (-5.0%), Industrial & Consumer $136.4M (-23.5%), Food & Beverage $99.6M (-20.2%), Energy $74.0M (+45.1%).
- Guidance cut: ATS no longer expects modest revenue growth or 50-75 bps margin expansion in fiscal 2027, after packaging orders were delayed by U.S. Section 338 tariffs on Canadian-made equipment (late August 2026); Q3 revenue expected at $640M-$680M.
- Fixed Cost Transformation Program: $65M-$75M of annualised savings (about 250 bps of margin), facility closures cutting about 10% of square footage, 300 to 400 fewer workers including subcontractors; $21.3M of restructuring in Q2.
- Net debt to pro forma adjusted EBITDA 3.1 times after buying back 2,244,461 shares for $61.3M; expected to stay moderately above the 2.0-3.0 times range for the rest of fiscal 2027. Two U.S. facilities sold after quarter end for $71.2M.
- Growth bets: radiopharmaceuticals (containment, automation, isotope production), nuclear (CANDU refurbishment, SMRs, fuel fabrication), data center infrastructure, services; fiscal 2027 capex now $60M-$80M.
- ATS Corporation Q2 fiscal 2027 earnings call transcript
- CEO Doug Wright and Interim CFO Anne Cybulski presented Q2 fiscal 2027 (November 4, 2026): bookings $827M, revenue $666M, adjusted margin 8.6% vs 10.9%.
- Life Sciences ended with its highest backlog on record ($1.2 billion); radiopharma was "a standout performer", with a large incremental order, plus medical device orders in diabetes care, vision care, sterilization and liquid pharma visual inspection.
- Section 338 tariffs hit packaging lines built in Canada and sold into the U.S.; they were removed at the end of October. Wright calls the unlock a "material positive order potential" but would not quantify it.
- Fiscal 2027 goals for modest revenue growth and margin expansion withdrawn; Q3 revenue guided at $640M-$680M.
- Fixed cost transformation: $65M-$75M of net annualised savings (about 250 bps), about half in COGS and half elsewhere; 300 to 400 job reductions; 10% of square footage cut; described as "very surgical", while ATS adds capacity in radiopharma (Bologna expansion, service centers in the central U.S. and Melbourne).
- Nuclear: orders from an existing SMR customer and a design order from a new one; U.S. domestic manufacturing expansion planned, U.K. entry under study.
- Capital allocation: about 2.2 million shares bought back for $61M; two senior leaders hired in corporate development and transformation; leverage 3.1x.
- ATS Corporation Q1 fiscal 2027 earnings call transcript
- Doug Wright's first portfolio review as CEO (Q1 fiscal 2027 call, August 6, 2026, with Interim CFO Anne Cybulski): he says ATS can, over time, operate above its 15% operating margin target.
- Path to 15%: about half from an 18-month fixed cost transformation program (around 250 bps), half from aftermarket services, commercial discipline, innovation and the ATS Business Model.
- First phase in Europe consolidates facilities and transfers capabilities, worth about $20M of annualised savings, about 30% of the total program.
- Q1: bookings $656M (-5.3%), adjusted revenues $698M (-5.2%), adjusted earnings from operations $68.1M (-13.4%), adjusted gross margin 30%; service-related revenues up 11%; Q2 revenue guided at $660M-$700M.
- Radiopharma is the fastest-growing part of life sciences, with a backlog twice the GLP-1 backlog; work with TerraPower isotopes; isotope sites are a "triple-digit" addressable opportunity per site.
- Nuclear: ATS's share of a reactor build could be $50M to $150M of revenue; engaged on SMRs and next-generation reactors in Canada and the U.S.
- Framework: cash return on investment applied to internal projects, M&A and possible disposals; no disposals on the agenda beyond transportation; leverage 2.9x.
Questions about ATS Corporation
What does ATS Corporation do?
ATS plans, designs, builds, commissions and services automated manufacturing and assembly systems, automation products and test solutions for life sciences, food and beverage, consumer, industrial and energy customers.
What was ATS's revenue in fiscal 2026?
Revenues were $2,972.9M in the year ended March 31, 2026, up 17.4%, with net income of $71.7M.
How many employees does ATS have?
Over 7,000 people, including approximately 2,200 engineers, at more than 65 manufacturing facilities and over 85 offices.
Who leads ATS Corporation?
Doug Wright is Chief Executive Officer, Anne Cybulski is Interim Chief Financial Officer and Michael Martino was selected as Chair of the Board.
What is ATS's strategy?
ATS follows a Build, Grow and Expand strategy, targets a 15% adjusted operating margin through fixed cost cuts and aftermarket growth, and invests in radiopharma and nuclear.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)